TrialStat EDC

Fast, Compliant, Fully Unified – EDC + IWRS + ePRO + Coding

TrialStat Portal

Real-Time Data & Analytics | Make Study Decision Sooner

Don't Settle For Standard EDC Technology & Services

With TrialStat EDC you'll have your studies up and running quicker, capture your study data more efficiently with fewer errors and reduce your overall study costs.

We're Supporting COVID-19 Research

In times of crisis we all need to step up and help. Effective immediately, we are offering TrialStat’s eClinical Platform and Data Analytics Portal at discounted rates to researchers working on solutions related to COVID-19. With a focus on ease of use, speed of implementation, and real-time data analytics, TrialStat’s data capture suite enables fast study start up and ensures all stakeholders have relevant, customized, timely insight into all aspects of study data and areas of risk or potential delays. We welcome the opportunity to collaborate with our industry colleagues on the path to treatments or cures – please contact [email protected] to learn more about this program.

Have questions about enrolling in a clinical trial, or about the COVID-19 Vaccines?

If you're a member of the general public and have questions about the approved vaccines, or are interested in enrolling in a clinical trial please have a look at the following resources:

From the entire TrialStat team, we wish you and yours good health as our industry and our communities work together to navigate this outbreak over the coming weeks and months. Thank you for #StayingHome and #FlatteningTheCurve!


Our Latest COVID-19 Research News

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Echocardiography Can Determine Mortality Risk in COVID-19 Patients

Excerpt from the Press Release: Echocardiography parameters and ARDS linked to higher mortality risk for hospitalized patients. Transthoracic ...
Read More

Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose

Excerpt from the Press Release: REDWOOD CITY, Calif.--(BUSINESS WIRE)--Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious ...
Read More

Selva to Present Preclinical Data at ASV 2021 Demonstrating Prophylactic and Therapeutic Oral Dosing of SLV213 for COVID-19 Protected Lungs from SARS-CoV-2-Induced Damage

Excerpt from the Press Release: SAN DIEGO--(BUSINESS WIRE)--Selva Therapeutics, Inc. (“Selva”) announced new preclinical data demonstrating SLV213, when given ...
Read More

Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™

Excerpt from the Press Release: MALVERN, Pa., July 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company ...
Read More

Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19

Excerpt from the Press Release: CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), ...
Read More

IncellDx: Two New Studies Offer a First Model for Diagnosing, Monitoring and Treating Long COVID

Excerpt from the Press Release: SAN CARLOS, Calif.--(BUSINESS WIRE)--Two new studies propose the first model for diagnosing, indexing ...
Read More

Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine

Excerpt from the Press Release: CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics ...
Read More

UK’s MHRA accepts Humanigen’s submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review

Excerpt from the Press Release: BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), today announced its submission for Marketing ...
Read More

Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients

Excerpt from the Press Release: PALO ALTO, Calif., July 6, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical ...
Read More